Rebif Generic Name & Formulations
Legal Class
Rx
General Description
Interferon beta-1a 8.8mcg/0.2mL, 22mcg/0.5mL, 44mcg/0.5mL; soln for SC inj; contains albumin (human); preservative-free.
Pharmacological Class
Immunomodulator.
How Supplied
Prefilled syringe (22mcg, 44mcg)—1, 12; Rebidose autoinjector (22mcg, 44mcg)—12; Titration Pack: Prefilled syringes or Rebidose autoinjectors (6×8.8mcg + 6×22mcg)—1
Manufacturer
Generic Availability
NO
Rebif Indications
Indications
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Rebif Dosage and Administration
Adult
Pre-medicate with analgesics and/or antipyretics on treatment days to ameliorate flu-like symptoms. Give by SC inj at least 48hrs apart, preferably in the PM. Rotate inj sites. Initially 4.4mcg 3 times per week for 2 weeks, titrate to target 22mcg 3 times per week by Week 5; or, initially 8.8mcg 3 times per week for 2 weeks, titrate to target 44mcg 3 times per week by Week 5. See full labeling. May need dose reduction if SGPT >5×ULN or leukopenia occurs.
Children
Not established.
Rebif Contraindications
Not Applicable
Rebif Boxed Warnings
Not Applicable
Rebif Warnings/Precautions
Warnings/Precautions
Depression; consider discontinuing if occurs. Suicidal ideation. Discontinue immediately if jaundice or other signs of liver dysfunction occur. Active or history of liver disease. Increased serum SGPT >2.5×ULN. Alcohol abuse. Seizure disorders. Risk of thrombotic microangiopathy; discontinue if occurs. History of thyroid dysfunction; do thyroid tests every 6 months. Monitor blood counts and liver function at 1, 3, and 6 months after initiation, then periodically thereafter. If myelosuppression, monitor CBCs with differential and platelets more intensively. Elderly. Pregnancy. Nursing mothers.
Rebif Pharmacokinetics
See Literature
Rebif Interactions
Interactions
Risk of hepatic injury with concomitant hepatotoxic drugs or alcohol.
Rebif Adverse Reactions
Adverse Reactions
Inj site reactions (necrosis, cellulitis, abscess, inflammation, pain), flu-like symptoms, abdominal pain, depression, elevated liver enzymes, hematologic abnormalities; rare: hepatic failure, anaphylaxis (discontinue if occurs).
Rebif Clinical Trials
Rebif Note
Not Applicable
Rebif Patient Counseling
Cost Savings Program
The Rebif patient support program is available here.